by QFR Solutions | Aug 24, 2018 | News
Source: FierceHealthcare Shareholders with both Cigna and Express Scripts voted to approve the insurer’s $67 billion acquisition of the PBM, the companies announced on Friday. The shareholder approval marks an important hurdle in finalizing the deal and follows...
by angelliu | Aug 3, 2018 | News
Source: FiercePharma Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land. Spain’s Almirall said Friday it had agreed to pick up a portfolio of medical dermatology products from the Dublin drugmaker...
by angelliu | Jul 31, 2018 | News
Source: Reuters FRANKFURT (Reuters) – Bayer has agreed to sell its established prescription dermatology brands to Denmark’s Leo Pharma, as the German drugmaker focuses on integrating seed maker Monsanto and on bolstering its drug development pipeline. The...
by angelliu | Jul 24, 2018 | News
Source: Sienna Biopharmaceuticals Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib),...
by QFR Solutions | Jul 12, 2018 | News
Source: FierceBiotech A new CSO isn’t all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British drugmaker’s dermatology drug tapinarof in a deal worth up to £250 million ($330 million). The asset is poised to enter...
by angelliu | Jul 10, 2018 | News
Source: Cassiopea Lainate, Italy – 10 July 2018 – Cassiopea SpA (SIX: SKIN), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced that top line...
